(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas

A total of no more than 20 people are expected to participate in this study at the Medical
College of Wisconsin/Froedtert Hospital. Patients will be followed for three years.

The usual treatment for sarcomas that spread to the lungs is to remove the cancer with
surgery. Patients who cannot have surgery or prefer not to have surgery, can receive
radiation therapy. Standard radiation therapy involves several weeks of daily treatment
sessions, although it is not as effective as surgery and may seriously damage normal
surrounding lung tissue. Stereotactic body radiation therapy (SBRT) is a radiation treatment
that gives fewer but higher doses of radiation than standard radiation. SBRT is used to treat
metastases to the lung from many types of cancer but has not been used very often with
patients who have metastatic disease to their lungs from sarcomas.

The purpose of this study is to test the possibility of SBRT to the lung for metastatic
disease to the lung. This information will be used to find out if there are factors that can
predict recovery or outcome of patients with metastatic disease to the lung from sarcoma.
SBRT will consist of 1 to 3 treatments per week for a total of 3 to 5 treatments to each
tumor until therapy is complete. After SBRT is completed, follow-up exams will occur 4-6
weeks from the completion of radiation treatment, every 3 months in year 1 and every 6 months
for 2 years.

Inclusion Criteria:

≥18 years of age Pathologic confirmation of primary soft tissue sarcoma with pathologic or
radiographic evidence of pulmonary metastatic disease No evidence of extra pulmonary
progression of disease for 3 months prior to enrollment on study.

1-5 pulmonary lesions all ≤5 cm in size. Medically inoperable or declines surgery Patients
may have had previous treatment for pulmonary metastases

Exclusion Criteria:

Patients who have uncontrolled extra-pulmonary disease Pregnant women Patients who have
greater than 5 pulmonary lesions at the time of study enrollment Patients who have disease
progression outside the lungs within 3 months of enrollment on the study.

Disease pathology other than sarcoma subtypes Patients with a history of metastatic disease
from a primary other than sarcoma